Drug Trial Radar · NCT07339514
A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.
Last checked: Nov 19, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Feb 11, 2025
Primary completion
Apr 1, 2026
Study completion May 30, 2026
Sponsor
- Lead sponsor
- ExoRNA BioscienceIndustry
- Sponsor type
- Industry
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose escalation and expansion clinical study to evaluate the safety, tolerability, PK profile and preliminary efficacy of ER2001 Injection vs. placebo in subjects with definitive diagnosis of early manifest HD. The study consists of a dose escalation phase (Part A, an open-label without placebo, which will be carried out firstly) and a dose expansion phase (Part B,randomized, blinded, placebo-controlled), both of which include a screening period (4 week prior to the first administration), a treatment period (for 6 consecutive weeks, once a week \[QW\] for 6 weeks), and a safety follow-up period (24 weeks).
Conditions
- Huntington Disease
Interventions
ER2001 intravenous injectionDrug
The drug dose is 0.08mg/kg, or 0.32mg/kg. The planned duration of each patient's treatment is 6 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 2, 3, 4, 5, and 6.
PlaceboDrug
Placebo Injection, The planned duration of the treatment is 6 weeks, and Placebo will be administrated intravenously at the first day of weeks 1, 2, 3, 4, 5, and 6.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of adverse events (AEs) and serious adverse events (SAEs).Time frame: Approximately 7.5 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.